China Issues Guidance To Promote Domestic Innovation And Facilitate Industry Consolidation
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Before the release of a new five-year plan, China's Ministry of Industry and Information Technology, the Ministry of Health and the State FDA jointly released new guidance Nov. 9 to expedite restructuring China's healthcare industry, a signal of the government's efforts to promote innovation and industry consolidation
You may also be interested in...
China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines
SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China
China Likely To Delay Drug Price Cuts Until Next Year: Good News Or Bad?
SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals
China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system